Терапевтический архив (Sep 2004)

A renoprotective effect of enalapril in chronictransplantation nephropathy

  • N A Tomilina,
  • A R Bagdasaryan,
  • E S Stolyarevich,
  • A V Sukhanov,
  • N D Fedorova,
  • I M Ilyinsky,
  • V V Tyrin,
  • A V Frolov

Journal volume & issue
Vol. 79, no. 9
pp. 47 – 52

Abstract

Read online

Aim. To study safety and efficacy of ACE inhibitor enalapril in chronic transplantation nephropathy (CTN) as well as nephroprotective efficacy of this drug in various clinical variants of CTN. Material and methods. A retrospective study covered 220 recipients with CRF. The patients were divided into the study group (n = 103) and the control group (n = 117). The study group was given ACE inhibitor enalapril the efficacy of which was assessed by arterial pressure (systolic, diastolic, mean) dynamics, 24 h proteinuria and the rate of CTN progression. This rate was suggested by probability of plasm creatinin doubling (Kaplan-Meier technique). Results. Enalapril significantly inhibited CTN progression running with minimal or marked proteinuria, had a pronounced hypotensive effect, promoted stabilization of minimal proteinuria (in CTN with minimal proteinuria) or reduction of protein excretion (in a proteinuric variant of CTN). Conclusion. Use of enalapril in CTN in a daily dose 10 mg maximum is safe and can be used for inhibition of CTN progression.

Keywords